Free Trial
NYSE:ELAN

Elanco Animal Health (ELAN) Stock Price, News & Analysis

$12.89
+0.07 (+0.55%)
(As of 07/26/2024 ET)
Today's Range
$12.77
$13.14
50-Day Range
$12.72
$18.45
52-Week Range
$8.52
$18.80
Volume
6.06 million shs
Average Volume
4.80 million shs
Market Capitalization
$6.37 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.57

Elanco Animal Health MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
36.3% Upside
$17.57 Price Target
Short Interest
Healthy
2.81% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-4.69
Upright™ Environmental Score
News Sentiment
0.30mentions of Elanco Animal Health in the last 14 days
Based on 15 Articles This Week
Insider Trading
Acquiring Shares
$254,700 Bought Last Quarter
Proj. Earnings Growth
10.75%
From $0.93 to $1.03 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.87 out of 5 stars

Medical Sector

233rd out of 936 stocks

Pharmaceutical Preparations Industry

102nd out of 436 stocks

ELAN stock logo

About Elanco Animal Health Stock (NYSE:ELAN)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

ELAN Stock Price History

ELAN Stock News Headlines

Kiss of death from Joe Biden
I did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.
ELAN Oct 2024 18.000 put
Kiss of death from Joe Biden
I did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.
See More Headlines
Receive ELAN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elanco Animal Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/08/2024
Today
7/26/2024
Next Earnings (Confirmed)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Fax
N/A
Employees
9,300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.57
High Stock Price Target
$21.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+36.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-1,231,000,000.00
Pretax Margin
-29.58%

Debt

Sales & Book Value

Annual Sales
$4.42 billion
Cash Flow
$2.27 per share
Book Value
$12.63 per share

Miscellaneous

Free Float
491,365,000
Market Cap
$6.37 billion
Optionable
Optionable
Beta
1.42
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Jeffrey N. SimmonsMr. Jeffrey N. Simmons (Age 57)
    President, CEO & Director
    Comp: $2.46M
  • Mr. Todd S. Young J.D.Mr. Todd S. Young J.D. (Age 52)
    Executive VP & CFO
    Comp: $1.11M
  • Dr. Ramiro Martin Cabral (Age 52)
    Executive Vice President of Elanco International
    Comp: $950.74k
  • Dr. Ellen de Brabander Ph.D. (Age 61)
    Executive Vice President of Innovation, Regulatory & Business Development
    Comp: $1.14M
  • Mr. Timothy J. Bettington (Age 50)
    Executive Vice President of Corporate Strategy & Market Development
    Comp: $1.19M
  • Mr. James M. Meer (Age 54)
    Senior VP & Chief Accounting Officer
  • Mr. Chris Keeley
    Senior VP & Chief Information Officer
  • Mr. David S. Kinard (Age 57)
    Executive Vice President of Human Resources, Corporate Communications & Administration
    Comp: $722.58k
  • Katy Grissom
    Head of Investor Relations
  • Ms. Shiv O'Neill (Age 50)
    Executive Vice President, General Counsel & Corporate Secretary

ELAN Stock Analysis - Frequently Asked Questions

How have ELAN shares performed this year?

Elanco Animal Health's stock was trading at $14.90 at the beginning of 2024. Since then, ELAN shares have decreased by 13.5% and is now trading at $12.89.
View the best growth stocks for 2024 here
.

How were Elanco Animal Health's earnings last quarter?

Elanco Animal Health Incorporated (NYSE:ELAN) posted its quarterly earnings data on Wednesday, May, 8th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.26 by $0.08. The company's revenue for the quarter was down 4.1% compared to the same quarter last year.

What is Jeff Simmons' approval rating as Elanco Animal Health's CEO?

169 employees have rated Elanco Animal Health Chief Executive Officer Jeff Simmons on Glassdoor.com. Jeff Simmons has an approval rating of 89% among the company's employees.

When did Elanco Animal Health IPO?

Elanco Animal Health (ELAN) raised $1.4 billion in an initial public offering (IPO) on Thursday, September 20th 2018. The company issued 62,900,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Barclays, BNP PARIBAS, BofA Merrill Lynch, Citigroup, Credit Suisse, Deutsche Bank Securities, Evercore ISI, Cowen, Academy Securities, Drexel Hamilton, Mischler Financial Group, Ramirez and The Williams Capital Group were co-managers.

Who are Elanco Animal Health's major shareholders?

Elanco Animal Health's top institutional investors include Douglas Lane & Associates LLC (0.75%), Bank of New York Mellon Corp (0.46%), Raymond James & Associates (0.25%) and Harbor Capital Advisors Inc. (0.09%). Insiders that own company stock include R David Hoover, Jeffrey N Simmons, John P Bilbrey, Rajeev A Modi, Michael J Harrington and Elanco Animal Health Inc.
View institutional ownership trends
.

How do I buy shares of Elanco Animal Health?

Shares of ELAN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Elanco Animal Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Elanco Animal Health investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), QUALCOMM (QCOM), Walt Disney (DIS), Johnson & Johnson (JNJ) and AT&T (T).

This page (NYSE:ELAN) was last updated on 7/27/2024 by MarketBeat.com Staff

From Our Partners